CytomX Therapeutics (NASDAQ:CTMX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.
Earnings
CytomX Therapeutics missed estimated earnings by 2.78%, reporting an EPS of $-0.37 versus an estimate of $-0.36.
Revenue was up $1.88 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.01 which was followed by a 0.62% increase in the share price the next day.
Here's a look at CytomX Therapeutics's past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.36 | -0.28 | -0.31 | -0.32 |
| EPS Actual | -0.37 | -0.40 | -0.35 | -0.30 |
| Revenue Estimate | 20.66M | 24.51M | 18.08M | 16.86M |
| Revenue Actual | 17.14M | 19.73M | 17.59M | 16.29M |
To track all earnings releases for CytomX Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
